Harvard Bioscience (HBIO) Assets Average (2011 - 2026)

Harvard Bioscience (HBIO) has reported Assets Average for 16 consecutive years, with $77.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Assets Average fell 3.55% year-over-year to $77.1 million in Q2 2026; TTM through Jun 2026 was $77.1 million, a 3.55% decrease from a year earlier, with the FY2025 full-year figure at $103.4 million, down 21.7% from the prior year.
• Assets Average was $77.1 million for Q2 2026 at Harvard Bioscience, down from $79.0 million in the prior quarter.
• Over five years, Assets Average peaked at $160.2 million in Q1 2022 and troughed at $77.1 million in Q2 2026.
• A 5-year average of $122.6 million and a median of $133.2 million in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average grew 4.19% in 2022 and slumped 39.23% in 2025, its largest moves.
• Over 5 years, Assets Average stood at $146.2 million in 2022, then decreased by 5.22% to $138.6 million in 2023, then declined by 6.94% to $128.9 million in 2024, then plunged by 38.71% to $79.0 million in 2025, then slipped by 2.43% to $77.1 million in 2026.
• The last three Assets Average figures came in at $77.1 million (Q2 2026), $79.0 million (Q1 2026), and $79.0 million (Q4 2025), per Business Quant data.